logo
Sign in or Register

Already a member?

Sign in

Or sign in with your account on:

Not a member yet?

Register
    

 


Rexahn Pharmaceuticals (RNN) Continues to Spike on Potential Cancer Pill, Roth Upgrade

By  +Follow January 13, 2014 10:17AM
Share:
Tickers Mentioned:

Shares in Rexahn Pharmaceuticals (RNN) jumped nearly 40 percent on Monday, continuing a bull-run that has the stock up over 150 percent since Thursday and over 265 percent in the last month on a promising potential cancer treatment and the initiation of relatively bullish coverage from Roth Capital Markets analysts.

RNN’s RX-3117 Could be Alternative for Eli Lilly’s Gemzar

Driving the current growth-spurt is the announcement of the initation of Phase 1b to study the safety and efficacy of RX-3117, Rexahn’s lead drug candidate, in cancer patients with solid tumors. The hype surrounding RX-3117 is considerable given that it has to potential to function as an oral to Eli Lilly’s (LLY) Gemzar.

"The initiation of this Phase I clinical trial of RX-3117 represents an important milestone for Rexahn," said CEO Peter D. Suzdak, Ph.D. "This compound is exciting to work with, as it has a unique profile with demonstrated activity against gemcitabine-resistant human cancer cells. We were pleased to see reduced side effect liability and oral bioavailability in cancer patients in our initial exploratory Phase I clinical trial conducted in Europe, and we believe that RX-3117 may represent a significant advancement in the treatment of cancer patients with solid tumors."

Gemzar is an injectable drug that results in resistance for 1 out of 4 patients, making an alternative that functions in pill form one with considerable commercial potential.

Analyst Seems Convinced

Also helping boost shares over the past few days was the news from Thursday that Roth Capital Markets’ Joe Pantiginis had initiated coverage on the stock at a “buy” rating with a price target of $3, still nearly double the current share price even after the spike in price.

Along with the considerable potential for RX-3117, the company boasts nearly $15 million in cash as well as over $5 million in new funding, giving it enough money to carry it for two years.

 

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Liked What You Read? Join Equities.com as a contributor and get eyeballs on your content FOR FREE!

Results for rnn
Brent Armstrong
28 Aug 15 07:05:34
$RNN holding very strong resistance in the .50's IMO low .50 is an excellent place to load up for a long term play https://t.co/ksA9q7omaO
WatchTheFunds
27 Aug 15 14:37:02
$RNN Institutional ownership up 37.22% Q/Q, with 7,392,070 net purchase http://t.co/5rroKuP2JY http://t.co/Q0OtWOQX85
Melissa
27 Aug 15 10:00:37
@imtheRealGL everything seems like it's poppin today $NVS $PFE $ANTM $CTIC $RXII $PBMD $OPXA $AMDA $RNN $ONOV
Life Sciences Report
27 Aug 15 06:31:21
"We expect $RNN's oncology pipeline, led by Archexin, to come into focus by year-end"- Andrew Fein. Read more: http://t.co/bf5SfxZx5P
brian sweetheart
27 Aug 15 06:13:03
Voted top trading group. http://t.co/5eVXN8RJLp Related: $RNN $WG $TRCH $UNIS $CPHI $CDTI
Sleek Money
26 Aug 15 23:35:51
Rexahn Pharmaceuticals Sees Significant Increase in Short Interest $RNN http://t.co/hd82HOETRl
StockNewsWires
26 Aug 15 23:25:02
$RNN: Rexahn Pharmaceuticals Sees Significant Increase in Short Interest …: http://t.co/97xaWtIsRk
Sleek Money
26 Aug 15 00:36:04
Rexahn Pharmaceuticals Sees Large Increase in Short Interest $RNN http://t.co/dzUgPnP1Ub
Dakota Financial
25 Aug 15 22:53:59
Rexahn Pharmaceuticals Sees Large Increase in Short Interest $RNN http://t.co/K4565tapmk
US Banking News
25 Aug 15 22:50:29
Rexahn Pharmaceuticals Sees Large Increase in Short Interest $RNN http://t.co/VVSJXehVAY
StockNewsWires
25 Aug 15 22:48:03
$RNN: Rexahn Pharmaceuticals Sees Large Increase in Short Interest (RNN): http://t.co/VxXihkabA8
Flaco Dahbi
25 Aug 15 05:16:22
$IBIO $TTHI $NBG $STEM $AMDA $RNN
NDUMISO M
25 Aug 15 02:11:51
RT @SharpResearchGp: WatchThese Stocks Xerox XRX Cascade CACB Lightbridge LTBR GlobeImmuneGBIM Charles&Colvard CHTR http://t.co/qzwvGkNQY7 …
dailystockplays.com
24 Aug 15 16:43:34
Aroon Positive http://t.co/6Qqnbj6Lxz $BWX $RGLD $TOTL $JNUG $CACQ $GGN $ACHI $FSM $CVOL $RNN $ASNB $NJMC $CPWY $TMSH $TBEV $NAMG
				
				
By  +Follow January 13, 2014 10:17AM
Share:

Comments

 

blog comments powered by Disqus

 Today's Must Reads

Welcome to Equities.com's Small-Cap Throwdown


These Analysts Called Apple's (AAPL) Collapse, Here's What They're Saying Now

7 Dow Stocks Worth Owning and a Lot that Aren't

Sprint Turnaround Has Begun


Saving the

Small-Cap Market

 

Small-cap stocks offer investors many benefits, ranging from higher growth potential to overlooked value opportuni... in Equities.com's Hangs on LockerDome

About us

Equities.com is an advanced financial data portal and social network designed to connect self-directed investors with the world’s most innovative startup and small cap companies. Through our in-depth coverage of small cap markets, comprehensive research and stock valuation reports, state of the art issuer products, and world class events, Equities.com provides the social tools and insight that drive tomorrow’s investment relationships and opportunities.

Market Data powered by QuoteMedia.
Copyright © QuoteMedia. Data delayed 15 minutes unless otherwise indicated. Terms of Use.

Login or Register

LOG IN